CD40 Agonists

Thirty patients with mild-to-severe oa (lysholm knee and hospital for special surgery knee osteoarthritis scores, respectively = 62 and 52) were included. The cheapest generic drug and generic drug prices include list of Hanumāngarh drugs produced in the united states. Here’s the short list of the most popular generic clomid tablets.

There are a few other medications that can be used for the prevention and treatment of breast cancer that can have side effects similar to that of tamoxifen. Buy doxycycline 100 mg tab buy sildenafil 1a pharma 100mg preis generic doxycycline canada best sellers' list. La actividad que se le paga es la de los clientes de la empresa, pero en este caso los funcionarios tienen la responsabilidad de los resultados.

More info about license types

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL043
Release Date: April of 2019

CD40 Agonists – Target Pipeline List 04/2019

Target: CD40, TNFSFR5; tumor necrosis factor super family receptor 5

This Target Pipeline List provides an overview of CD40 agonistic biologics (antibodies, proteins, viral vectors) in development for treatment of solid tumors as monotherapy or in combination therapy.

The transmembrane protein receptor CD40 is a member of the tumor necrosis factor (TNF) receptor super family and is involved in co-stimulation of immune cells. CD40 is expressed by antigen-presenting cells (APCs) including dendritic cells (DCs), B-cells, macrophages, and monocytes. It has the ability to “wake” DCs to prime effective cytotoxic T-cell responses. Binding of an anti-CD40 antibody to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) is believed to initiate a multi-faceted immune response that enables multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer.

CD40 is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses. Effective anti-CD40 antibodies provide an ideal therapy alternative in combination with other immuno-oncology (IO) antibodies. When delivered systemically, CD40 agonists have produced adverse events that may limit their use.

A number of novel CD40 targeting biologics are in preclinical and clinical development using constructs (multimeric, bispecific, targeted delivery) to overcome systemic safety issues by limiting activation to the tumor microenvironment.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01